High levels of FLT3-ligand in bone marrow and peripheral blood
of patients with advanced multiple myeloma

J 2017

High levels of FLT3-ligand in bone marrow and peripheral blood of patients with advanced multiple myeloma

STEINER, Normann, Roman HAJEK, Sabina ŠEVČÍKOVÁ, Bojana BORJAN, Karin JÖHRER et. al.

Basic information

Original name

High levels of FLT3-ligand in bone marrow and peripheral blood of patients with advanced multiple myeloma

Authors

STEINER, Normann (40 Austria), Roman HAJEK (203 Czech Republic), Sabina ŠEVČÍKOVÁ (203 Czech Republic, guarantor, belonging to the institution), Bojana BORJAN (40 Austria), Karin JÖHRER (40 Austria), Georg GÖBEL (40 Austria), Gerold UNTERGASSER (40 Austria) and Eberhard GUNSILIUS (40 Austria)

Edition

Plos one, San Francisco, Public Library of Science, 2017, 1932-6203

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 2.766

RIV identification code

RIV/00216224:14110/17:00097567

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1371/journal.pone.0181487

UT WoS

000406634500078

Keywords in English

Multiple myeloma

Abstract

V originále

Introduction Multiple myeloma (MM) is still incurable due to resistance against various therapies. Thus, the identification of biomarkers predicting progression is urgently needed. Here, we evaluated four biomarkers in bone marrow and peripheral blood of MM patients for their prognostic significance. Materials & methods Bone marrow- and peripheral blood plasma levels of FLT3-L, soluble TIE2, endostatin, and osteoactivin were determined in patients with monoclonal gammopathy of undetermined significance (MGUS, n = 14/n = 4), patients with newly diagnosed MM (NDMM, n = 42/n = 31) and patients with relapsed/refractory MM (RRMM, n = 27/n = 16) by sandwich ELISA. Results Median FLT3-L expression increased from MGUS (58.77 pg/ml in bone marrow; 80.40 pg/ml in peripheral blood) to NDMM (63.15 pg/ml in bone marrow; 85.05 pg/ml in peripheral blood) and was maximal in RRMM (122 pg/ml in bone marrow; 160.47 pg/ml in peripheral blood; NDMM vs. RRMM p<0.001). A cut-off value of FLT3-L >92 pg/ml in bone marrow and >121 pg/ml in peripheral blood was associated with relapse or refractoriness in MM patients. FLT3-L was found to be a high predictive marker for discrimination between NDMM and RRMM as well in bone marrow as in peripheral blood (AUC 0.75 in bone marrow; vs 0.84 in peripheral blood). Conclusion High levels of FLT3-L in bone marrow and peripheral blood of MM patients identify patients with progressive disease and are associated with relapse or refractoriness in MM patients. FLT3-L could be useful as a marker to identify RRMM patients and should be evaluated as target for future therapies.

Citovat

STEINER, Normann, Roman HAJEK, Sabina ŠEVČÍKOVÁ, Bojana BORJAN, Karin JÖHRER, Georg GÖBEL, Gerold UNTERGASSER and Eberhard GUNSILIUS. High levels of FLT3-ligand in bone marrow and peripheral blood of patients with advanced multiple myeloma. Plos one. San Francisco: Public Library of Science, 2017, vol. 12, No 7, p. 1-14. ISSN 1932-6203. Available from: https://dx.doi.org/10.1371/journal.pone.0181487.

@article{1389451,
   author = {Steiner, Normann and Hajek, Roman and Ševčíková, Sabina and Borjan, Bojana and Jöhrer, Karin and Göbel, Georg and Untergasser, Gerold and Gunsilius, Eberhard},
   article_location = {San Francisco},
   article_number = {7},
   doi = {http://dx.doi.org/10.1371/journal.pone.0181487},
   keywords = {Multiple myeloma},
   language = {eng},
   issn = {1932-6203},
   journal = {Plos one},
   title = {High levels of FLT3-ligand in bone marrow and peripheral blood of patients with advanced multiple myeloma},
   volume = {12},
   year = {2017}
}

TY  - JOUR
ID  - 1389451
AU  - Steiner, Normann - Hajek, Roman - Ševčíková, Sabina - Borjan, Bojana - Jöhrer, Karin - Göbel, Georg - Untergasser, Gerold - Gunsilius, Eberhard
PY  - 2017
TI  - High levels of FLT3-ligand in bone marrow and peripheral blood of patients with advanced multiple myeloma
JF  - Plos one
VL  - 12
IS  - 7
SP  - 1-14
EP  - 1-14
PB  - Public Library of Science
SN  - 19326203
KW  - Multiple myeloma
N2  - Introduction Multiple myeloma (MM) is still incurable due to resistance against various therapies. Thus, the identification of biomarkers predicting progression is urgently needed. Here, we evaluated four biomarkers in bone marrow and peripheral blood of MM patients for their prognostic significance. Materials & methods Bone marrow- and peripheral blood plasma levels of FLT3-L, soluble TIE2, endostatin, and osteoactivin were determined in patients with monoclonal gammopathy of undetermined significance (MGUS, n = 14/n = 4), patients with newly diagnosed MM (NDMM, n = 42/n = 31) and patients with relapsed/refractory MM (RRMM, n = 27/n = 16) by sandwich ELISA. Results Median FLT3-L expression increased from MGUS (58.77 pg/ml in bone marrow; 80.40 pg/ml in peripheral blood) to NDMM (63.15 pg/ml in bone marrow; 85.05 pg/ml in peripheral blood) and was maximal in RRMM (122 pg/ml in bone marrow; 160.47 pg/ml in peripheral blood; NDMM vs. RRMM p<0.001). A cut-off value of FLT3-L >92 pg/ml in bone marrow and >121 pg/ml in peripheral blood was associated with relapse or refractoriness in MM patients. FLT3-L was found to be a high predictive marker for discrimination between NDMM and RRMM as well in bone marrow as in peripheral blood (AUC 0.75 in bone marrow; vs 0.84 in peripheral blood). Conclusion High levels of FLT3-L in bone marrow and peripheral blood of MM patients identify patients with progressive disease and are associated with relapse or refractoriness in MM patients. FLT3-L could be useful as a marker to identify RRMM patients and should be evaluated as target for future therapies.
ER  -

STEINER, Normann, Roman HAJEK, Sabina ŠEVČÍKOVÁ, Bojana BORJAN, Karin JÖHRER, Georg GÖBEL, Gerold UNTERGASSER and Eberhard GUNSILIUS. High levels of FLT3-ligand in bone marrow and peripheral blood of patients with advanced multiple myeloma. \textit{Plos one}. San Francisco: Public Library of Science, 2017, vol.~12, No~7, p.~1-14. ISSN~1932-6203. Available from: https://dx.doi.org/10.1371/journal.pone.0181487.

Detailed Information on Publication Record